Dr. Appleman is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
5115 Centre Ave
Pittsburgh, PA 15232Phone+1 412-692-4724Fax+1 412-692-4905
Education & Training
- Brigham and Women's Hospital/Massachusetts General Hospital/Dana-Farber Cancer InstituteFellowship, Hematology and Medical Oncology, 1998 - 2001
- Beth Israel Deaconess Medical CenterResidency, Internal Medicine, 1995 - 1998
- New York University School of MedicineClass of 1995
Certifications & Licensure
- PA State Medical License 2006 - 2024
- MA State Medical License 1998 - 2006
- American Board of Internal Medicine Medical Oncology
Awards, Honors, & Recognition
- Regional Top Doctor Castle Connolly, 2014
Clinical Trials
- A Study of Imatinib and Docetaxel in Prostate Cancer Start of enrollment: 2005 Aug 01
- Study of Oxaliplatin and Taxotere in Prostate Cancer Start of enrollment: 2004 Nov 01
- MUC1 Vaccine in Conjunction With Poly-ICLC in Patients With Recurrent and/or Advanced Prostate Cancer Start of enrollment: 2006 Jun 01
- Join now to see all
Publications & Presentations
PubMed
- SWOG/NCI Phase II Dual Anti-CTLA-4/PD-1 Blockade in Rare Tumors: Nonepithelial Ovarian Cancer.Young Kwang Chae, Megan Othus, Sandip Pravin Patel, Kelly J Wilkinson, Emily M Whitman-Purves
Clinical Cancer Research. 2024-12-16 - 1 citationsRandomized, Double-Blind Phase III Study of Pazopanib Versus Placebo in Patients With Metastatic Renal Cell Carcinoma Who Have No Evidence of Disease After Metastasect...Leonard J Appleman, Se Eun Kim, Wayne B Harris, Sumanta K Pal, Michael R Pins
Journal of Clinical Oncology. 2024-06-10 - Pembrolizumab and Enzalutamide in Patients with Abiraterone Acetate-Pretreated Metastatic Castration-Resistant Prostate Cancer: Cohort C of the Phase 1b/2 KEYNOTE-365 ...Evan Y Yu, William R Berry, Howard Gurney, Margitta Retz, Henry J Conter
European Urology Oncology. 2024-06-01
Lectures
- Randomized, double-blind phase III study of pazopanib versus placebo in patients with metastatic renal cell carcinoma who have no evidence of disease following metasta...2019 ASCO Annual Meeting - 6/1/2019
- Safety and activity of hydroxychloroquine and aldesleukin in metastatic renal cell carcinoma: A cytokine working group phase II study.2018 ASCO Annual Meeting - Chicago, Illinois - 06/2/2018
Press Mentions
- The Society for Immunotherapy of Cancer (SITC) Invites You to Attend the Virtual Press Briefing of the Society’s 36th Anniversary Annual MeetingNovember 2nd, 2021
- Pazopanib Found Not Beneficial Following Metastasectomy in Metastatic RCCJune 14th, 2019
- No Benefit from Pazopanib in Advanced Kidney Cancer After Surgery to Remove MetastasesJune 3rd, 2019
- Join now to see all
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: